AYTU BioPharma to Present at Lytham Partners Spring 2026 Investor Conference

AYTU BioPharma, Inc. will take part in the Lytham Partners Spring 2026 Investor Conference on May 28. The company specialises in developing medicines for complex central nervous system diseases. It will host a webcast presentation and hold virtual one-on-one meetings during the event. The webcast presentation is scheduled for 9:15 AM Eastern time on May 28, 2026. Attendees can access it via the conference home page or a direct link. A replay will be available afterwards on the company’s website.

Management will engage in virtual meetings with investors throughout the day. AYTU BioPharma focuses on treatments for conditions like major depressive disorder and ADHD. Its prescription products include EXXUATM (gepirone) extended-release tablets for depression.

The company is dedicated to providing its medications through patient access programmes. These efforts aim to ensure broad availability of its innovative therapies. The event offers investors insight into AYTU BioPharma’s work and pipeline. The webcast and meetings will highlight its commitment to advancing central nervous system treatments. Replays and access details remain available for those unable to attend live.